Lupus & antiphospholipid syndrome
ANA-positive versus ANA-negative Antiphospholipid Antibody-positive Patients: Results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Clinical Database and Repository (“Registry”)
Authors' conclusion
When we analysed aPL-positive patients with no other SARDs, ANA status was not associated with thrombosis or pregnancy morbidity.
Study context
- Population
- aPL-positive patients with or without Revised Sapporo APS classification criteria, without concomitant systemic autoimmune rheumatic diseases (SARDs), APS ACTION Registry56% ANA+, 44% ANA-negative (ANA-)
- Participants
- 430 patients
- Exposure
- ANA-positive vs ANA-negative aPL-positive patients
- Outcome
- Prevalence and impact of ANA in aPL-positive patients without concomitant SARDs
Methodological detailsmulticentre registry
- Multicentre registry
Main finding
As reported in the abstract
Observational data: associations, not effects.
Further findings
History of haematologic manifestations (persistent autoimmune haemolytic anaemia, thrombocytopenia, leukopenia and/or lymphopenia)
P = 0.006
- Triple aPL-positivity
- P = 0.02
- Low baseline C3 and C4 levels · low C3
- P = 0.05
- Low baseline C3 and C4 levels · low C4
- P = 0.009
- Arthritis in aPL-positive patients with no APS classification (subgroup)
- P = 0.006
- Number of pregnancies, women with ≥1 pregnancy (subgroup: 113 ANA+, 96 ANA-)
- P = 0.018
- Number of live births, women with ≥1 pregnancy (subgroup)
- P = 0.014
- HCQ treatment
- P < 0.001
Triple aPL-positivity
- More frequent in ANA+
Low baseline C3 and C4 levels
- More frequent in ANA+
ENA
- Higher frequency in ANA+
Arthritis in aPL-positive patients with no APS classification (subgroup)
- Higher rate in ANA+
Number of pregnancies, women with ≥1 pregnancy (subgroup: 113 ANA+, 96 ANA-)
- Higher in ANA-
Number of live births, women with ≥1 pregnancy (subgroup)
- Higher in ANA-
HCQ treatment
- Wider proportion treated in ANA+
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →